trending Market Intelligence /marketintelligence/en/news-insights/trending/_6evv1svsilxqoylrksd1w2 content esgSubNav
In This List

Deciphera Pharmaceuticals starts common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Deciphera Pharmaceuticals starts common stock offering

Deciphera Pharmaceuticals Inc. started an offering to sell 3,750,000 common shares.

The company also plans to grant the underwriters an option to buy up to 562,500 shares.

J.P. Morgan and Piper Jaffray are acting as joint book-running managers for the offering.

Waltham, Mass.-based Deciphera Pharmaceuticals is a biotechnology company that develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread.